Drug Trial Radar · NCT06037148
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Last checked: Nov 19, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 7, 2023
Primary completion
Mar 6, 2024
Study completion Mar 6, 2024
Sponsor
- Lead sponsor
- Desentum OyIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults. As an explorative objective, the trial will also investigate the effect of DM-101PX on the allergic symptoms following birch pollen allergen exposure in a chamber. Expanded access to the study treatment is not available.
Conditions
- Birch Pollen Allergy
Interventions
DM-101PXBiological
subcutaneous injection of DM-101PX
Placebo to Match DM-101PXBiological
Placebo to match DM-101PX administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse EventsTime frame: From the first dose to until 14-28 days from the last dose
- Adverse Events of Special InterestTime frame: From the first dose to until 14-28 days from the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research
Mississauga, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.